Baker Avenue Asset Management’s Charles River Laboratories CRL Stock Holding History

Baker Avenue Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$343K	Sell	1,511 -56	-4%	-$9.97K	0.01%	643
2026 Q1	$270K	Sell	1,567 -156	-9%	-$28.9K	0.01%	638
2025 Q4	$344K	Sell	1,723 -93	-5%	-$16.9K	0.01%	469
2025 Q3	$284K	Buy	+1,816	New	+$288K	0.01%	489
2023 Q4	–	Sell	-59	Closed	-$11.6K	–	603
2023 Q3	$11.6K	Buy	59 +56	+1,867%	+$11.5K	﹤0.01%	737
2023 Q2	$631	Buy	+3	New	+$597	﹤0.01%	1329
2023 Q1	–	Sell	-29	Closed	-$6.32K	–	1640
2022 Q4	$6.32K	Buy	+29	New	+$6.33K	﹤0.01%	776

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Baker Avenue Asset Management's CRL Position: Q2 2026 in Review

Baker Avenue Asset Management reduced its Charles River Laboratories (CRL) stake by 3.6% in Q2 2026, selling an estimated $9.97K and leaving 1,511 shares worth $343K. The position accounts for 0.01% of the portfolio, ranked #643.

Baker Avenue Asset Management first reported a position in CRL in Q4 2022 and has held it in 7 quarters since. The position peaked at $344K in Q4 2025. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Baker Avenue Asset Management held 1,511 shares of Charles River Laboratories worth $343K as of Q2 2026.
Baker Avenue Asset Management sold 56 Charles River Laboratories shares in Q2 2026, an estimated $9.97K.
Charles River Laboratories made up 0.01% of Baker Avenue Asset Management's portfolio in Q2 2026, its #643 holding.
Baker Avenue Asset Management first reported a position in Charles River Laboratories in Q4 2022 and has held it in 7 quarters since.
Baker Avenue Asset Management's Charles River Laboratories position peaked at $344K in Q4 2025.
565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.